1022157-23-8

Basic information

• Product Name: (Z)-1-(2-amino-1,2-dicyanovinyl)-3-(2-methoxyphenyl)urea
• Synonyms: (Z)-1-(2-amino-1,2-dicyanovinyl)-3-(2-methoxyphenyl)urea
• CAS NO: 1022157-23-8
• Molecular Weight: 257.252
• Mol File: 1022157-23-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (Z)-1-(2-amino-1,2-dicyanovinyl)-3-(2-methoxyphenyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-1-(2-amino-1,2-dicyanovinyl)-3-(2-methoxyphenyl)urea(1022157-23-8)
• EPA Substance Registry System: (Z)-1-(2-amino-1,2-dicyanovinyl)-3-(2-methoxyphenyl)urea(1022157-23-8)

Safety Data

• Hazardous Substances Data: 1022157-23-8(Hazardous Substances Data)

Upstream product

• 700-87-8 1-Isocyanato-2-methoxy-benzene 
• 1187-42-4 diaminomaleonitrile 
• 18514-52-8 2,3-diaminomaleonitrile 

Downstream Products

• 1022155-05-0 2-(4-hydroxyphenyl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide 
• 1022158-92-4 tert-butyl 4-(6-carbamoyl-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)benzylcarbamate 
• 1022155-23-2 9-(2-methoxyphenyl)-8-oxo-2-(quinolin-5-yl)-8,9-dihydro-7H-purine-6-carboxamide 
• 1022155-25-4 2-cyclopentyl-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide 

Relevant articles and documents

PURINE COMPOUNDS POSSESSING ANTICANCER ACTIVITY

The present disclosure provides compounds of Formulas (I') and (I), and pharmaceutically acceptable salts thereof. The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses thereof for treating proliferative diseases.

HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS

Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.